Agenus (AGEN) Competitors

Inhibrx Biosciences currently has a consensus price target of $150.00, suggesting a potential upside of 44.75%. Agenus has a consensus price target of $19.50, suggesting a potential upside of 141.04%. Given Agenus' higher probable upside, analysts clearly believe Agenus is more favorable than Inhibrx Biosciences.

Agenus has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Agenus has a net margin of 69.33% compared to Inhibrx Biosciences' net margin of 0.00%. Agenus' return on equity of -47.68% beat Inhibrx Biosciences' return on equity.

Inhibrx Biosciences has a beta of 3.51, meaning that its stock price is 251% more volatile than the broader market. Comparatively, Agenus has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 6.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 3 articles in the media. Inhibrx Biosciences' average media sentiment score of 0.60 beat Agenus' score of 0.06 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Agenus has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Agenus has a net margin of 69.33% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Agenus' return on equity.

61.5% of Agenus shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 6.5% of Agenus shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Agenus presently has a consensus target price of $19.50, suggesting a potential upside of 141.04%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 132.92%. Given Agenus' higher possible upside, research analysts clearly believe Agenus is more favorable than Immatics.

Agenus has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

In the previous week, Immatics had 2 more articles in the media than Agenus. MarketBeat recorded 5 mentions for Immatics and 3 mentions for Agenus. Agenus' average media sentiment score of 0.06 beat Immatics' score of -0.35 indicating that Agenus is being referred to more favorably in the media.

Replimune Group has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Agenus has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Agenus has a net margin of 69.33% compared to Replimune Group's net margin of 0.00%. Agenus' return on equity of -47.68% beat Replimune Group's return on equity.

In the previous week, Replimune Group had 19 more articles in the media than Agenus. MarketBeat recorded 22 mentions for Replimune Group and 3 mentions for Agenus. Replimune Group's average media sentiment score of 0.18 beat Agenus' score of 0.06 indicating that Replimune Group is being referred to more favorably in the media.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 5.4% of Replimune Group shares are held by insiders. Comparatively, 6.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Replimune Group presently has a consensus price target of $11.86, indicating a potential downside of 19.72%. Agenus has a consensus price target of $19.50, indicating a potential upside of 141.04%. Given Agenus' higher possible upside, analysts clearly believe Agenus is more favorable than Replimune Group.

Agenus has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Agenus currently has a consensus price target of $19.50, suggesting a potential upside of 141.04%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 130.52%. Given Agenus' higher possible upside, research analysts clearly believe Agenus is more favorable than Corvus Pharmaceuticals.

Agenus has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

61.5% of Agenus shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Agenus has a net margin of 69.33% compared to Corvus Pharmaceuticals' net margin of 0.00%. Corvus Pharmaceuticals' return on equity of -36.15% beat Agenus' return on equity.

Agenus has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

In the previous week, Agenus and Agenus both had 3 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.20 beat Agenus' score of 0.06 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.